Vorapaxar — Membership Pricing

Other medications in Heart & Cardiovascular

• Warfarin
• Adenosine
• Alirocumab
• Ambrisentan
• Amlodipine
• Apixaban
• Atenolol
• Atorvastatin

What Vorapaxar is approved for (FDA label)

ZONTIVITY is a protease-activated receptor-1 (PAR-1) antagonist indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). ZONTIVITY has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke, and urgent coronary revascularization. ( 1.1 ) 1.1 Patients with History of Myocardial Infarction (MI) or with Peripheral Arterial Disease (PAD) ZONTIVITY ® is indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). ZONTIVITY has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke, and urgent coronary revascularization (UCR).

Source: Read the full FDA label on DailyMed. Label effective date: October 18, 2022.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Vorapaxar (FDA label)

WARNING: BLEEDING RISK Do not use ZONTIVITY in patients with a history of stroke, transient ischemic attack (TIA), or intracranial hemorrhage (ICH); or active pathological bleeding [see CONTRAINDICATIONS (4.1 , 4.2) ] . Antiplatelet agents, including ZONTIVITY, increase the risk of bleeding, including ICH and fatal bleeding [see Warnings and Precautions (5.1) ]. WARNING: BLEEDING RISK See full prescribing information for complete boxed warning. Do not use ZONTIVITY in patients with a history of stroke, transient ischemic attack (TIA), or intracranial hemorrhage (ICH); or active pathological bleeding. ( 4.1 , 4.2 ) Antiplatelet agents, including ZONTIVITY, increase the risk of bleeding, including ICH and fatal bleeding. ( 5.1 )

Source: FDA prescribing information (DailyMed). Set ID: f2abe3ed-ed3d-4215-a489-b18341ce85bc. SPL document ID: eb55583e-2701-6426-e053-2a95a90abb4f. Label effective date: October 18, 2022. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Vorapaxar (FDA label)

ZONTIVITY tablets, 2.08 mg vorapaxar, are yellow, oval-shaped, film-coated tablets with "351" on one side. Tablets: 2.08 mg vorapaxar. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: f2abe3ed-ed3d-4215-a489-b18341ce85bc. SPL document ID: eb55583e-2701-6426-e053-2a95a90abb4f. Label effective date: October 18, 2022. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Vorapaxar (FDA label)

The following serious adverse reaction is also discussed elsewhere in the labeling: Bleeding [see Boxed Warning and Warnings and Precautions (5.1) ] . Bleeding, including life-threatening and fatal bleeding, is the most commonly reported adverse reaction. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact WraSer Pharmaceuticals at 1-800-988-6115 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Source: FDA prescribing information (DailyMed). Set ID: f2abe3ed-ed3d-4215-a489-b18341ce85bc. SPL document ID: eb55583e-2701-6426-e053-2a95a90abb4f. Label effective date: October 18, 2022. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Vorapaxar (FDA label)

History of stroke, TIA, or ICH. ( 4.1 ) Active pathologic bleeding. ( 4.2 ) 4.1 History of Stroke, Transient Ischemic Attack (TIA), or Intracranial Hemorrhage (ICH) ZONTIVITY is contraindicated in patients with a history of stroke, TIA, or ICH because of an increased risk of ICH in this population [see Adverse Reactions (6) ] . Discontinue ZONTIVITY in patients who experience a stroke, TIA, or ICH [see Adverse Reactions (6.1) and Clinical Studies (14) ] . 4.2 Active Pathologic Bleeding ZONTIVITY is contraindicated in patients with active pathological bleeding such as ICH or peptic ulcer [see Warnings and Precautions (5.1) and Adverse Reactions (6.1) ] .

Source: FDA prescribing information (DailyMed). Set ID: f2abe3ed-ed3d-4215-a489-b18341ce85bc. SPL document ID: eb55583e-2701-6426-e053-2a95a90abb4f. Label effective date: October 18, 2022. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Vorapaxar (FDA label)

Like other antiplatelet agents, ZONTIVITY increases the risk of bleeding. ( 5.1 ) Avoid use with strong CYP3A inhibitors or inducers. ( 5.2 ) 5.1 General Risk of Bleeding Antiplatelet agents, including ZONTIVITY, increase the risk of bleeding, including ICH and fatal bleeding [see Adverse Reactions (6.1) ] . ZONTIVITY increases the risk of bleeding in proportion to the patient's underlying bleeding risk. Consider the underlying risk of bleeding before initiating ZONTIVITY. General risk factors for bleeding include older age, low body weight, reduced renal or hepatic function, history of bleeding disorders, and use of certain concomitant medications (e.g., anticoagulants, fibrinolytic therapy, chronic nonsteroidal anti-inflammatory drugs [NSAIDS], selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors) increases the risk of bleeding [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3) ] . Avoid concomitant use of warfarin or other anticoagulants.

Source: FDA prescribing information (DailyMed). Set ID: f2abe3ed-ed3d-4215-a489-b18341ce85bc. SPL document ID: eb55583e-2701-6426-e053-2a95a90abb4f. Label effective date: October 18, 2022. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Vorapaxar (FDA label)

7.1 Effects of Other Drugs on ZONTIVITY Vorapaxar is eliminated primarily by metabolism, with contributions from CYP3A4 and CYP2J2. Strong CYP3A Inhibitors Avoid concomitant use of ZONTIVITY with strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, posaconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, boceprevir, telaprevir, telithromycin and conivaptan) [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3) ] . Strong CYP3A Inducers Avoid concomitant use of ZONTIVITY with strong inducers of CYP3A (e.g., rifampin, carbamazepine, St. John's Wort and phenytoin) [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3) ].

Source: FDA prescribing information (DailyMed). Set ID: f2abe3ed-ed3d-4215-a489-b18341ce85bc. SPL document ID: eb55583e-2701-6426-e053-2a95a90abb4f. Label effective date: October 18, 2022. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.